Galectins comprise a family of soluble β-galactoside binding proteins, which regulate key biological processes including cell growth, differentiation, apoptosis, and immune responses.
Sixteen galectin genes have been identified in animal kingdoms, 12 of which are expressed in humans.Galectins are typically divided into three groups based on their structural characteristics: (i) prototypical galectins (Galectin-1 (Gal1), Gal2, Gal5, Gal7, Gal10, Gal11, Gal 13, Gal14, and Gal15), which are characterized by asingle CRD and can function as monomers or form homodimers; (ii) the chimeric galectin Gal3 (the only member of this class), which has asingle CRD and a Galectins have recently been linked to important therapeutic factors that affect whether a variety of anticancer treatment modalities, such as chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies are effective or ineffective.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
![]() |
V86851 | (2S)-Selvigaltin | (2S)-Selvigaltin is the S-isomer of selvigaltin. | |
![]() |
V83485 | 6Lac[6]Met | 1132892-04-6 | |
![]() |
V74909 | DB21, Galectin-1 Antagonist | 1623027-80-4 | DB21, Galectin-1 Antagonist is a dibenzofuran-conjugated peptide mimetic that works as an allosteric inhibitor of galectin-1 (GAL1) binding to cell surface glycans. |
![]() |
V76994 | G3-C12 TFA | G3-C12 (TFA) is a galectin-3 binding peptide with Kd of 88 nM and has anti-tumor activity. | |
![]() |
V74910 | Galectin-3 antagonist 1 | 2921603-03-2 | Galectin-3 antagonist 1 (compound 15) is a potent and specific Galectin-3 (Gal-3) antagonist (inhibitor) with a Kd of 5.3 μM. |
![]() |
V74911 | Galectin-3 antagonist 2 | 2921603-02-1 | Galectin-3 is a β-galactoside-specific carbohydrate recognition protein (lectin) that has the ability to promote the migration of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and withstand drug treatment. |
![]() |
V74912 | Galectin-3-IN-2 | 2883648-71-1 | Galectin-3-IN-2 (Compound 9) is a potent multivalent galectin-3 (Gal-3; IC50=8.3 μM) inhibitor. |
![]() |
V86847 | Galectin-3-IN-3 | 2491661-50-6 | Galectin-3-IN-3 (compound 4) is an orally active and selective Gal-3 inhibitor with IC50 values of 11 nM and 84 nM for mGal-3 and hGal-3, respectively. |
![]() |
V86850 | Galectin-3-IN-4 | 2496515-38-7 | Galectin-3-IN-4 (compound 5) is a carboxamide analog. |
![]() |
V99835 | Galectin-3-IN-5 | Galectin-3-IN-5 (Compound 20) is an orally active galectin-3 (Gal-3) inhibitor with IC50 of 9.2 nM for hGal-3. | |
![]() |
V79555 | Galectin-3/galectin-8-IN-1 | Galectin-3/galectin-8-IN-1 (Compound 53) is a dual galectin-3 and galectin-8 C-terminal domain inhibitor (antagonist) with K d values of 4.12 μM and 6.04 μM, respectively. | |
![]() |
V79556 | Galectin-3/galectin-8-IN-2 | Galectin-3/galectin-8-IN-2 (Compound 57) is a dual galectin-3 and galectin-8 C-terminal domain inhibitor (antagonist) with Kds of 12.8 μM and 2.06 μM, respectively. | |
![]() |
V86849 | Galectin-4-IN-3 | 1044566-26-8 | Galectin-4-IN-3 (Compound 11) is a galectin 4C inhibitor with Kd of 160 μM. |
![]() |
V80258 | Galectin-8-IN-1 | 3028946-23-5 | Galectin-8-IN-1 is a selective ligand of galectin-8N, with a Kd of 48 μM. |
![]() |
V83388 | Galectin-8-IN-2 | 1044566-24-6 | |
![]() |
V74913 | Galectin-8N-IN-1 | 2667628-25-1 | Galectin-8N-IN-1 (compound 19a) is a potent and specific galectin-8N inhibitor (antagonist) with a Kd of 1.8 μM. |
![]() |
V99747 | Galectin-8N-IN-2 | Galectin-8N-IN-2 (Compound 2) is a potent and selective Galectin-8N inhibitor with a Ki value of 74 μM. | |
![]() |
V21523 | GB1107 | 1978336-61-6 | GB1107 (GB-1107) is a novel, potent, selective, orally bioavailable galectin-3 (GAL-3) inhibitor with anticancer activity. |
![]() |
V85894 | GB1490 | 2172866-22-5 | |
![]() |
V86848 | GB1908 | GB1908 is a selective oral galectin-1 inhibitor with Ki values of 57 nM and 72 nM for human and mouse galectin-1, respectively. |